Prelude Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-245
| Closed | -$11K | – | 996 |
|
|
2020
Q3 | $11K | Buy |
245
+59
| +32% | +$2.65K | ﹤0.01% | 1084 |
|
|
2020
Q2 | $9K | Hold |
186
| – | – | ﹤0.01% | 1081 |
|
|
2020
Q1 | $10K | Sell |
186
-1,194
| -87% | -$64.2K | ﹤0.01% | 746 |
|
|
2019
Q4 | $85K | Buy |
+1,380
| New | +$85K | ﹤0.01% | 791 |
|
|
2018
Q4 | – | Sell |
-116
| Closed | -$10K | – | 1479 |
|
|
2018
Q3 | $10K | Sell |
116
-62
| -35% | -$5.35K | ﹤0.01% | 1098 |
|
|
2018
Q2 | $21K | Buy |
+178
| New | +$21K | ﹤0.01% | 1074 |
|
|
2018
Q1 | – | Sell |
-146
| Closed | -$9K | – | 1399 |
|
|
2017
Q4 | $9K | Sell |
146
-412
| -74% | -$25.4K | ﹤0.01% | 1074 |
|
|
2017
Q3 | $26K | Sell |
558
-146
| -21% | -$6.8K | ﹤0.01% | 1145 |
|
|
2017
Q2 | $25K | Sell |
704
-2,031
| -74% | -$72.1K | ﹤0.01% | 1098 |
|
|
2017
Q1 | $84K | Sell |
2,735
-3,267
| -54% | -$100K | 0.01% | 791 |
|
|
2016
Q4 | $201K | Sell |
6,002
-6,278
| -51% | -$210K | 0.02% | 546 |
|
|
2016
Q3 | $327K | Buy |
12,280
+5,455
| +80% | +$145K | 0.03% | 366 |
|
|
2016
Q2 | $150K | Buy |
6,825
+5,125
| +301% | +$113K | 0.02% | 554 |
|
|
2016
Q1 | $50K | Buy |
+1,700
| New | +$50K | 0.01% | 899 |
|
|
2015
Q3 | – | Sell |
-7,400
| Closed | -$333K | – | 1459 |
|
|
2015
Q2 | $333K | Buy |
7,400
+6,000
| +429% | +$270K | 0.05% | 386 |
|
|
2015
Q1 | $43K | Sell |
1,400
-2,100
| -60% | -$64.5K | 0.01% | 1320 |
|
|
2014
Q4 | $178K | Sell |
3,500
-720
| -17% | -$36.6K | 0.03% | 649 |
|
|
2014
Q3 | $167K | Buy |
+4,220
| New | +$167K | 0.02% | 716 |
|